Why the study?
The mechanisms of HFpEF remain unclear, leading to little progress in effective treatment, while arterial stiffness is an independent risk factor for cardiovascular disorders including diastolic dysfunction.
This perspective highlights the mechanistic link between arterial stiffness and HFpEF, emphasizing the urgent need for new targeted pharmacologic therapies.
Arterial stiffness assessment may aid HFpEF risk stratification; leaves open whether targeted pharmacologic therapies improve outcomes.
Cardiovascular diseases are the leading cause of mortality in the world. Heart failure with preserved ejection fraction (HFpEF) accounts for about half of all heart failure. Unfortunately, the mechanisms of HFpEF are still unclear, leading to little progress of effective treatment of HFpEF. Arterial stiffness is the decrement of arterial compliance. The media of large arteries degenerate in both physiological and pathological conditions. Many studies have proven that arterial stiffness is an independent risk factor for cardiovascular disorders including diastolic dysfunction. In this perspective, we discussed if arterial stiffness is related to HFpEF, and how does arterial stiffness contribute to HFpEF. Finally, we briefly summarized current treatment strategies on arterial stiffness and HFpEF. Though some new drugs were developed, the safety and effectiveness were not adequately assessed. New pharmacologic treatment for arterial stiffness and HFpEF are urgently needed.
No takes yet. Share an insight, caveat, or question.
Chi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: